OrthoPediatrics to Participate in the 21st Annual Needham Virtual Healthcare Conference
Get Alerts KIDS Hot Sheet
Join SI Premium – FREE
WARSAW, Ind., March 31, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Mark Throdahl, Executive Chairman, are scheduled to participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022.
| Event: | 21st Annual Needham Virtual Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Tuesday, April 12, 2022 |
| Time: | 12:45pm ET |
An audio webcast of the presentation will be available online at the OrthoPediatrics’ investor relations website, http://ir.orthopediatrics.com. Additionally, a replay will be available for 90 days after the presentation.
About OrthoPediatrics Corp.Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 36 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 45 countries outside the United States.
Investor ContactsMatt Bacso, CFAGilmartin Group[email protected]
Source: OrthoPediatrics Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apeing Opens Stage 3 of $APEING Presale at $0.0004 as Project Advances Its 33-Stage Token Sale
- Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
- PwC US and PwC India Form Joint Venture to Help Clients Grow and Compete at Greater Speed and Scale
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share